share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股SEC公告 ·  05/31 09:03
Moomoo AI 已提取核心信息
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
On May 31, 2024, Novo Integrated Sciences, Inc. announced the approval by its Board of Directors of a Stock Repurchase Program, authorizing the repurchase of up to $5 million of the company's common stock. The repurchases may occur in the open market or through privately negotiated transactions, depending on market conditions and other factors. Additionally, the Board is reviewing the possibility of increasing the repurchase amount, contingent upon the availability of excess funds from a program designed to monetize a Standby Letter of Credit, which is part of the Ophir Collection acquisition strategy. The timing and volume of repurchases will be subject to management's discretion, considering factors such as stock price, market conditions, and the company's capital position. The program does not commit Novo Integrated Sciences to a specific number of shares and may be suspended at any time. The announcement was made in a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
2024 年 5 月 31 日,Novo Integrated Sciences, Inc. 宣布其董事会批准了一项股票回购计划,授权回购公司高达 500 万美元的普通股。回购可以在公开市场上进行,也可以通过私下谈判的交易进行,具体取决于市场条件和其他因素。此外,董事会正在审查增加回购金额的可能性,视一项旨在通过备用信用证获利的计划中是否有剩余资金而定,该计划是Ophir Collection收购战略的一部分。回购的时间和数量将由管理层酌情决定,考虑股价、市场状况和公司资本状况等因素。该计划不承诺Novo Integrated Sciences持有特定数量的股份,并可能随时暂停。该公告是在该公司向美国证券交易委员会提交的8-K表最新报告附录99.1所附的新闻稿中宣布的。
2024 年 5 月 31 日,Novo Integrated Sciences, Inc. 宣布其董事会批准了一项股票回购计划,授权回购公司高达 500 万美元的普通股。回购可以在公开市场上进行,也可以通过私下谈判的交易进行,具体取决于市场条件和其他因素。此外,董事会正在审查增加回购金额的可能性,视一项旨在通过备用信用证获利的计划中是否有剩余资金而定,该计划是Ophir Collection收购战略的一部分。回购的时间和数量将由管理层酌情决定,考虑股价、市场状况和公司资本状况等因素。该计划不承诺Novo Integrated Sciences持有特定数量的股份,并可能随时暂停。该公告是在该公司向美国证券交易委员会提交的8-K表最新报告附录99.1所附的新闻稿中宣布的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息